Assessment of competitive and mechanism-based inhibition by clarithromycin: Use of domperidone as a CYP3A probe-drug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes

Drug Metabolism Letters

Volumn 4, Issue 2, 2010, Pages 69-76

  Michaud, Veronique ^a   Turgeon, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Clarithromycin; CYP3A4; CYP3A5; Cytochrome b5< inf>; Cytochromes P450; Domperidone; Drug metabolism; Inhibition; Metabolic intermediate complex

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOMPERIDONE; ANTIINFECTIVE AGENT; CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DISACCHARIDE; DOPAMINE RECEPTOR BLOCKING AGENT; DRUG; LACTOBIONIC ACID;

ARTICLE; CELL CULTURE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN CELL; LIVER CELL; LIVER MICROSOME; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BIOASSAY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM;

ANTI-BACTERIAL AGENTS; BINDING, COMPETITIVE; BIOLOGICAL ASSAY; CELLS, CULTURED; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; DISACCHARIDES; DOMPERIDONE; DOPAMINE ANTAGONISTS; HEPATOCYTES; HUMANS; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS;

EID: 77953759267     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231210791292717     Document Type: Article

References (36)

1. Becker, M. L.; Kallewaard, M.; Caspers, P. W.; Visser, L. E.; Leufkens, H. G.; Stricker, B. H. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf., 2007, 16(6), 641-51.
2. Hanrahan, J. P.; Choo, P. W.; Carlson, W.; Greineder, D.; Faich, G. A.; Platt, R. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann. Epidemiol., 1995, 5(3), 201-9.
3. Paris, D. G.; Parente, T. F.; Bruschetta, H. R.; Guzman, E.; Niarchos, A. P. Torsades de pointes induced by erythromycin and terfenadine. Am. J. Emerg. Med., 1994, 12(6), 636-8.
4. Tsai, W. C.; Tsai, L. M.; Chen, J. H. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J. Formos. Med. Assoc., 1997, 96(2), 144-6.
5. Desta, Z.; Kerbusch, T.; Flockhart, D. A. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6(CYP2D6). Clin. Pharmacol. Ther., 1999, 65(1), 10-20.
6. Vitola, J.; Vukanovic, J.; Roden, D. M. Cisapride-induced torsades de pointes. J. Cardiovasc. Electrophysiol., 1998, 9(10), 1109-13.
7. Glassman, A. H.; Bigger, J. T. Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry., 2001, 158(11), 1774-82.
8. Zimmermann, M.; Duruz, H.; Guinand, O.; Broccard, O.; Levy, P.; Lacatis, D.; Bloch, A. Torsades de Pointes after treatment with terfenadine and ketoconazole. Eur. Heart J., 1992, 13(7), 1002-3.
9. Zhou, S.; Yung Chan, S.; Cher Goh, B.; Chan, E.; Duan, W.; Huang, M.; McLeod, H. L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet., 2005, 44(3), 279-304.
10. Zhou, S.; Chan, E.; Duan, W.; Huang, M.; Chen, Y. Z. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev., 2005, 37(1), 41-213.
11. Zhou, S.; Chan, E.; Lim, L. Y.; Boelsterli, U. A.; Li, S. C.; Wang, J.; Zhang, Q.; Huang, M.; Xu, A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab., 2004, 5(5), 415-42.
12. Lindstrom, T. D.; Hanssen, B. R.; Wrighton, S. A. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob. Agents Chemother., 1993, 37(2), 265-9.
13. Okudaira, T.; Kotegawa, T.; Imai, H.; Tsutsumi, K.; Nakano, S.; Ohashi, K. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J. Clin. Pharmacol., 2007, 47(7), 871-6.
14. Masubuchi, Y.; Horie, T. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Crit. Rev. Toxicol., 2007, 37(5), 389-412.
15. Mayhew, B. S.; Jones, D. R.; Hall, S. D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos., 2000, 28(9), 1031-7.
16. Michaud, V.; Simard, C.; Turgeon, J. An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies. J Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 852(1-2), 611-6.
17. Michaud, V.; Simard, C.; Turgeon, J. Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of Cytochrome b5 and inhibition by ketoconazole.. Drug Metab. Lett., 2010, Submitted.
18. Pessayre, D.; Tinel, M.; Larrey, D.; Cobert, B.; Funck-Brentano, C.; Babany, G. Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione. J. Pharmacol. Exp. Ther., 1983, 224(3), 685-91.
19. Pessayre, D.; Descatoire, V.; Konstantinova-Mitcheva, M.; Wandscheer, J. C.; Cobert, B.; Level, R.; Benhamou, P. J.; Jaouen, M.; Mansuy, D. Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450. Biochem. Pharmacol., 1981, 30(6), 553-8.
20. Omura, T.; Sato, R. The Carbon Monoxide-Binding Pigment Of Liver Microsomes. I. Evidence For Its Hemoprotein Nature. J. Biol. Chem., 1964, 239, 2370-8.
21. Goutelle, S.; Maurin, M.; Rougier, F.; Barbaut, X.; Bourguignon, L.; Ducher, M.; Maire, P. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam. Clin. Pharmacol., 2008, 22(6), 633-48.
22. Benet, L. Z. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol. Interv., 2005, 5(2), 79-83.
23. Wang, Y. H.; Jones, D. R.; Hall, S. D. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab. Dispos., 2005, 33(5), 664-71.
24. Williams, J. A.; Ring, B. J.; Cantrell, V. E.; Jones, D. R.; Eckstein, J.; Ruterbories, K.; Hamman, M. A.; Hall, S. D.; Wrighton, S. A. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos., 2002, 30(8), 883-91.
25. Yamazaki, H.; Nakamura, M.; Komatsu, T.; Ohyama, K.; Hatanaka, N.; Asahi, S.; Shimada, N.; Guengerich, F. P.; Shimada, T.; Nakajima, M.; Yokoi, T. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr. Purif., 2002, 24(3), 329-37.
26. Hirota, N.; Ito, K.; Iwatsubo, T.; Green, C. E.; Tyson, C. A.; Shimada, N.; Suzuki, H.; Sugiyama, Y. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm. Drug Dispos., 2001, 22(2), 53-71.
27. Yamaori, S.; Yamazaki, H.; Suzuki, A.; Yamada, A.; Tani, H.; Kamidate, T.; Fujita, K.; Kamataki, T. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450(CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem. Pharmacol., 2003, 66(12), 2333-40.
28. Allqvist, A.; Miura, J.; Bertilsson, L.; Mirghani, R. A. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur. J. Clin. Pharmacol., 2007, 63(2), 173-9.
29. Ohmori, S.; Ishii, I.; Kuriya, S.; Taniguchi, T.; Rikihisa, T.; Hirose, S.; Kanakubo, Y.; Kitada, M. Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab. Dispos., 1993, 21(2), 358-63.
30. Tinel, M.; Descatoire, V.; Larrey, D.; Loeper, J.; Labbe, G.; Letteron, P.; Pessayre, D. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J. Pharmacol. Exp. Ther., 1989, 250(2), 746-51.
31. Jones, D. R.; Gorski, J. C.; Hamman, M. A.; Mayhew, B. S.; Rider, S.; Hall, S. D. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther., 1999, 290(3), 1116-25.
32. Ernest, C. S. 2nd; Hall, S. D.; Jones, D. R. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther., 2005, 312(2), 583-91.
33. Larrey, D.; Funck-Brentano, C.; Breil, P.; Vitaux, J.; Theodore, C.; Babany, G.; Pessayre, D. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem. Pharmacol., 1983, 32(6), 1063-8.
34. Kanamitsu, S.; Ito, K.; Green, C. E.; Tyson, C. A.; Shimada, N.; Sugiyama, Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm. Res., 2000, 17(4), 419-26.
35. Bartkowski, R. R.; Goldberg, M. E.; Larijani, G. E.; Boerner, T. Inhibition of alfentanil metabolism by erythromycin. Clin. Pharmacol. Ther., 1989, 46(1), 99-102.
36. Ohashi, K.; Sudo, T.; Sakamoto, K.; Tateishi, T.; Fujimura, A.; Kumagai, Y.; Ebihara, A. The influence of pretreatment periods with diltiazem on nifedipine kinetics. J. Clin. Pharmacol., 1993, 33(3), 222-5.